Staff

Pemakluman Penggunaan Label Keselamatan Hologram Baharu Dan Kaedah Pengesahan Ketulenan Label Bagi Produk Farmaseutikal

Date: 17 December 2025 - 4:31pm

Sukacita dimaklumkan bahawa Kementerian Kesihatan Malaysia (KKM) telah melaksanakan penggunaan label keselamatan hologram FarmaTag versi baharu bagi produk ubat-ubatan sebagai langkah meningkatkan keselamatan, ketulenan serta integriti produk di pasaran berkuat kuasa 2 Oktober 2025.

Invitation to Engagement Sessions on Medicines Price Mechanism and Cost Benefit Analysis (CBA)

Sukacita dimaklumkan bahawa Program Perkhidmatan Farmasi, Kementerian Kesihatan Malaysia (KKM) akan mengadakan sesi penerangan secara atas talian berkaitan status terkini Mekanisme Harga Ubat dan kajian Cost Benefit Analysis (CBA) bagi impak pelaksanaannya terhadap pihak berkepentingan.

Jemputan sesi penerangan ini adalah terbuka kepada semua pihak yang berkaitan mengikut 3 kumpulan pihak berkepentingan seperti berikut:

Sesi/Kumpulan

Tarikh

Location/place: 
Online
Date: 
Monday, 4 January 2021 to Wednesday, 6 January 2021

BE CAUTIOUS WHEN BUYING MEDICINES ONLINE

Date: 19 September 2019 - 2:38pm

For further information, kindly visit to https://www.pharmacy.gov.my/v2/en/website/waspada-belian-ubat-online

PN. NORMAWATI BINTI MOHAMED NOOR,

SEKSYEN KAWAL SELIA IKLAN UBAT,

CAWANGAN KAWALAN IKLAN,

BAHAGIAN PENGUATKUASAAN FARMASI, KKM

normawati_mn@moh.gov.my

03-78413239

10th National Pharmacy R&D Conference 2018 (Open for Registration)

Pharmaceutical Services Programme, Ministry of Health Malaysia will be organising the 10th National Pharmacy R&D Conference on 9-11 July 2018. Theme of the conference is "Enhancing Access To Medicines Through Value-Based Approaches". Participation of all pharmacy researchers are welcome. Conference and pre-conference workshop are now open for registration. Registration form and relevant information can be obtained through website www.10RnDPharmacy.org.my.

Location/place: 
Royale Chulan Hotel, Seremban
Date: 
Monday, 9 July 2018 to Wednesday, 11 July 2018

Aktiviti Penyelenggaraan Sistem Program Perkhidmatan Farmasi

Date: 28 September 2017 - 8:15am

Adalah dimaklumkan, bermula tarikh 29 September 2017 jam 5.00 petang sehingga 2 Oktober 2017 jam 12 tengah hari akan berlaku gangguan terdapat semua sistem di bawah Program Perkhidmatan Farmasi. Ini bagi memberi laluan kepada kerja-kerja penyelenggaraan elektrik untuk peningkatan mutu perkhidmatan Kerajaan sedia ada.

Berikut adalah senarai sistem-sistem yang akan mengalami gangguan capaian sepanjang tempoh tersebut:

Management of Leprosy Drug (Multidrug Therapy) from WHO to be Used at the Government's Healthcare Facilities.

Date: 18 October 2016 - 11:42am

This Standard Operating Procedures (SOP) is intended to provide guidance for healthcare providers in managing leprosy drugs received from the World Health Organisation (WHO).

English

Respiratory Medication Therapy Adherence Clinic Protocol: Asthma/COPD (Adult & Paediatric) 2nd Edition 2015

Date: 7 December 2017 - 4:44pm

Taking into account changes in current practice and the introduction of newer medicines and devices used in the management of asthmatic and Chronic Obstructive Pulmonary Disorder (COPD) patients, it is timely to review and publish this second edition of Respiratory Medication Therapy Adherence Clinic (RMTAC) Protocol. This updated protocol will also help ensure the standardisation of practice and contribute towards the expansion of RMTAC service throughout Ministry Of Health facilities; both in primary and secondary care settings.

 

English

Garis Panduan untuk Pemantauan Keselamatan Produk Erythropoietin Stimulating Agents (ESAs) & Pelaporan Kesan Advers Pure Red Cell Aplasia (PRCA)

Date: 14 April 2016 - 2:45pm

Pure Red Cell Aplasia (PRCA) is one of the adverse effects due to usage of Erythropoietin Stimulating Agents (ESAs).  The definition for PRCA is as follows:

‘Epoiten-associated pure red cell aplasia (PRCA) is characterized by severe anemia, low reticulocyte count, erythroblasts absence, epoetin non-response, and neutralizing antibodies against erythropoietin (EPO).  PRCA is a rare adverse effect resulting from antibodies to Erythropoietin Stimulating Agents (ESAs) that cross-react with endogenous erythropoietin.’

English

9th National Pharmacy R&D Conference 2016 (2nd Announcement)

Location/place: 
Kuala Lumpur/Putrajaya
Date: 
Monday, 8 August 2016 to Wednesday, 10 August 2016

Pages